Talis Biomedical Corp Stock Net Income
| TLIS Stock | USD 2.84 0.00 0.00% |
As of the 6th of February, Talis Biomedical has the Coefficient Of Variation of 812.4, variance of 91.0, and Risk Adjusted Performance of 0.1017. In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Talis Biomedical Corp, as well as the relationship between them. Please validate Talis Biomedical Corp risk adjusted performance, variance, as well as the relationship between the Variance and kurtosis to decide if Talis Biomedical is priced more or less accurately, providing market reflects its prevalent price of 2.84 per share. Please also confirm Talis Biomedical Corp information ratio, which is currently at 0.1184 to double-check the company can sustain itself at a future point.
Talis Biomedical's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Talis Biomedical's valuation are provided below:Talis Biomedical Corp does not presently have any fundamental trend indicators for analysis. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. Talis |
Talis Biomedical 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Talis Biomedical's pink sheet what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Talis Biomedical.
| 11/08/2025 |
| 02/06/2026 |
If you would invest 0.00 in Talis Biomedical on November 8, 2025 and sell it all today you would earn a total of 0.00 from holding Talis Biomedical Corp or generate 0.0% return on investment in Talis Biomedical over 90 days. Talis Biomedical is related to or competes with Gilead Sciences, Sanofi ADR, Amgen, Merck, and Novo Nordisk. Talis Biomedical Corporation operates as a molecular diagnostic company More
Talis Biomedical Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Talis Biomedical's pink sheet current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Talis Biomedical Corp upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | 0.1184 | |||
| Maximum Drawdown | 77.5 |
Talis Biomedical Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Talis Biomedical's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Talis Biomedical's standard deviation. In reality, there are many statistical measures that can use Talis Biomedical historical prices to predict the future Talis Biomedical's volatility.| Risk Adjusted Performance | 0.1017 | |||
| Jensen Alpha | 1.2 | |||
| Total Risk Alpha | 0.7192 | |||
| Treynor Ratio | (1.06) |
Talis Biomedical February 6, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.1017 | |||
| Market Risk Adjusted Performance | (1.05) | |||
| Mean Deviation | 2.31 | |||
| Coefficient Of Variation | 812.4 | |||
| Standard Deviation | 9.54 | |||
| Variance | 91.0 | |||
| Information Ratio | 0.1184 | |||
| Jensen Alpha | 1.2 | |||
| Total Risk Alpha | 0.7192 | |||
| Treynor Ratio | (1.06) | |||
| Maximum Drawdown | 77.5 | |||
| Skewness | 8.12 | |||
| Kurtosis | 66.0 |
Talis Biomedical Corp Backtested Returns
Talis Biomedical is dangerous given 3 months investment horizon. Talis Biomedical Corp owns Efficiency Ratio (i.e., Sharpe Ratio) of 0.13, which indicates the firm had a 0.13 % return per unit of risk over the last 3 months. We were able to collect and analyze data for sixteen different technical indicators, which can help you to evaluate if expected returns of 1.25% are justified by taking the suggested risk. Use Talis Biomedical Corp Risk Adjusted Performance of 0.1017, coefficient of variation of 812.4, and Variance of 91.0 to evaluate company specific risk that cannot be diversified away. Talis Biomedical holds a performance score of 10 on a scale of zero to a hundred. The entity has a beta of -1.1, which indicates a somewhat significant risk relative to the market. As the market becomes more bullish, returns on owning Talis Biomedical are expected to decrease slowly. On the other hand, during market turmoil, Talis Biomedical is expected to outperform it slightly. Use Talis Biomedical Corp information ratio and rate of daily change , to analyze future returns on Talis Biomedical Corp.
Auto-correlation | 0.00 |
No correlation between past and present
Talis Biomedical Corp has no correlation between past and present. Overlapping area represents the amount of predictability between Talis Biomedical time series from 8th of November 2025 to 23rd of December 2025 and 23rd of December 2025 to 6th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Talis Biomedical Corp price movement. The serial correlation of 0.0 indicates that just 0.0% of current Talis Biomedical price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.0 | |
| Spearman Rank Test | 1.0 | |
| Residual Average | 0.0 | |
| Price Variance | 0.0 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, Talis Biomedical Corp reported net income of (62.01 Million). This is 118.17% lower than that of the Health Care Equipment & Supplies sector and 126.04% lower than that of the Health Care industry. The net income for all United States stocks is 110.86% higher than that of the company.
Talis Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Talis Biomedical's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Talis Biomedical could also be used in its relative valuation, which is a method of valuing Talis Biomedical by comparing valuation metrics of similar companies.Talis Biomedical is currently under evaluation in net income category among its peers.
Talis Fundamentals
| Return On Equity | -0.7 | |||
| Return On Asset | -0.3 | |||
| Operating Margin | (113.60) % | |||
| Current Valuation | (38.24 M) | |||
| Shares Outstanding | 1.82 M | |||
| Shares Owned By Insiders | 8.30 % | |||
| Shares Owned By Institutions | 52.15 % | |||
| Number Of Shares Shorted | 17.96 K | |||
| Price To Book | 0.06 X | |||
| Price To Sales | 19.57 X | |||
| Revenue | 412 K | |||
| Gross Profit | (149.4 M) | |||
| EBITDA | (60.7 M) | |||
| Net Income | (62.01 M) | |||
| Cash And Equivalents | 165.37 M | |||
| Cash Per Share | 6.21 X | |||
| Total Debt | 19.67 M | |||
| Debt To Equity | 0.19 % | |||
| Current Ratio | 12.51 X | |||
| Book Value Per Share | 26.68 X | |||
| Cash Flow From Operations | (53.24 M) | |||
| Short Ratio | 0.59 X | |||
| Earnings Per Share | (28.02) X | |||
| Target Price | 5.0 | |||
| Number Of Employees | 99 | |||
| Beta | 1.62 | |||
| Market Capitalization | 7.98 M | |||
| Total Asset | 98.34 M | |||
| Retained Earnings | (539.96 M) | |||
| Working Capital | 68.91 M | |||
| Net Asset | 98.34 M |
About Talis Biomedical Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Talis Biomedical Corp's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Talis Biomedical using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Talis Biomedical Corp based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Talis Pink Sheet Analysis
When running Talis Biomedical's price analysis, check to measure Talis Biomedical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Talis Biomedical is operating at the current time. Most of Talis Biomedical's value examination focuses on studying past and present price action to predict the probability of Talis Biomedical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Talis Biomedical's price. Additionally, you may evaluate how the addition of Talis Biomedical to your portfolios can decrease your overall portfolio volatility.